TNFRSF10A and melanoma: Exogenous treatment with IL-32α inhibited proliferation and increased apoptosis in HTB-72 human melanoma cell lines in relation to the upregulation of p21, p53, and TRAIL receptor 1 (TRAILR1) [58].